Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DC Bead regulatory update

Eisai disclosed in its 1Q13 earnings that DC Bead was

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE